Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(18):1417-1418; doi:10.1093/jnci/djg068
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Spyratos, F.
Right arrow Articles by Hacène, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spyratos, F.
Right arrow Articles by Hacène, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

CORRESPONDENCE

Re: Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer

Frédérique Spyratos, Cécile Bouchet, Magali Ferrero-Poüs, Michèle Tubiana-Hulin, Kamel Hacène

Affiliations of authors: F. Spyratos (Laboratoire d‘Oncobiologie), C. Bouchet, M. Ferrero-Poüs (Département de Biologie), M. Tubiana-Hulin (Département de Médecine), K. Hacène (Département de Statistiques Médicales), Centre René Huguenin de Lutte Contre le Cancer, Saint Cloud, France.

Correspondence to: Dr. Frédérique Spyratos, Centre René Huguenin de Lutte Contre le Cancer, Laboratoire d’Oncobiologie, 35 rue Dailly, 92210 Saint Cloud, France (e-mail: f.spyratos@stcloud-huguenin.org).

The first 10% of the full text of this article appears below.

Recent clinical data (1) suggest that c-erbB-2 overexpression/amplification might be associated with tamoxifen resistance in patients with estrogen receptor (ER)-positive tumors. This association is controversial, however, and the question of the efficacy of hormone therapy in these patients is still a matter of debate. In a recent issue of the Journal, Konecny et al. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?